Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer

Cited by (1,003)

Items 101–200 of 1,003

1. Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment
   Koji Haratani, Hidetoshi Hayashi, Taro Tanaka, Hiroyasu Kaneda, Yosuke Togashi, Kazuko Sakai, K. Hayashi, Shuta Tomida, Yasutaka Chiba, Kimio Yonesaka et al. · 2017 · Annals of Oncology
2. The blood–tumour barrier in cancer biology and therapy
   Patricia Schriver Steeg · 2021 · Nature Reviews Clinical Oncology
3. Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS
   Y.-L. Wu, D. Planchard, Shun Lü, Hao Sun, N. Yamamoto, Dongwook Kim, Daniel Shao-Weng Tan, James Chih‐Hsin Yang, M. Azrif, Tetsuya Mitsudomi et al. · 2018 · Annals of Oncology
4. Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: Mechanisms and therapeutic strategies
   Sun Min Lim, Nicholas L. X. Syn, Byoung Chul Cho, Ross Andrew Soo · 2018 · Cancer Treatment Reviews
5. Genetic and non-genetic clonal diversity in cancer evolution
   James R. Black, Nicholas McGranahan · 2021 · Nature reviews. Cancer
6. Emerging concepts in liquid biopsies
   Samantha O. Perakis, Michael R. Speicher · 2017 · BMC Medicine
7. Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis
   Vassiliki A. Papadimitrakopoulou, Tony S.K. Mok, Ji‐Youn Han, Myung‐Ju Ahn, Angelo Delmonte, Suresh S. Ramalingam, Seung‐Whan Kim, Frances A. Shepherd, Janessa J. Laskin, Yong He et al. · 2020 · Annals of Oncology
8. Invasion and metastasis in cancer: molecular insights and therapeutic targets
   Yongxing Li, Fengshuo Liu, Qingjin Cai, Lijun Deng, Qin Ouyang, Xiang H.-F. Zhang, Ji Zheng · 2025 · Signal Transduction and Targeted Therapy
9. Emerging role of tumor cell plasticity in modifying therapeutic response
   Siyuan Qin, Jingwen Jiang, Yi Lü, Edouard Collins Nice, Canhua Huang, Jian Zhang, Weifeng He · 2020 · Signal Transduction and Targeted Therapy
10. Covalent Inhibition in Drug Discovery
    Ghosh, Avick Kumar, Samanta, Indranil, Mondal, Anushree, Liu, Wenshe Ray · 2019 · ChemMedChem
11. Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations
    Anqi Lin, Ting Wei, Hui Meng, Peng Luo, Jian Zhang · 2019 · Molecular Cancer
12. A Convergence-Based Framework for Cancer Drug Resistance
    Konieczkowski, David J., Johannessen, Cory M., Garraway, Levi A. · 2018 · Cancer Cell
13. Mechanism of Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and a Potential Treatment Strategy
    Tatsuya Nagano, Motoko Yoshikawa TACHIHARA, Yoshihiro Nishimura · 2018 · Cells
14. Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in EGFR Mutation–Positive Non–Small Cell Lung Cancer
    Kohsuke Isomoto, Koji Haratani, Hidetoshi Hayashi, Shigeki Shimizu, Shuta Tomida, Takashi Niwa, Toshihide Yokoyama, Yasushi Fukuda, Yasutaka Chiba, Ryoji Kato et al. · 2020 · Clinical Cancer Research
15. CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials
    Goss, G., Tsai, C.-M., Shepherd, F.A., Ahn, M.-J., Bazhenova, L., Crinò, L., de Marinis, F., Felip, E., Morabito, A., Hodge, R. et al. · 2018 · Annals of Oncology
16. Next Generation Sequencing (NGS): A Revolutionary Technology in Pharmacogenomics and Personalized Medicine in Cancer
    Morganti, Stefania, Tarantino, Paolo, Ferraro, Emanuela, D’Amico, Paolo, Duso, Bruno Achutti, Curigliano, Giuseppe · 2019 · Advances in Experimental Medicine and Biology
17. Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial
    Shun Lü, Lin Wu, Hong Jian, Ying Chen, Qiming Wang, Jian Fang, Ziping Wang, Yanping Hu, Meili Sun, Liang Han et al. · 2022 · The Lancet Oncology
18. Whole-Brain Radiotherapy for Brain Metastases: Evolution or Revolution?
    Paul D. Brown, Manmeet Singh Ahluwalia, Osaama H. Khan, Anthony L. Asher, Jeffrey Scott Wefel, Vinai Gondi · 2017 · Journal of Clinical Oncology
19. Current Landscape of Non-Small Cell Lung Cancer: Epidemiology, Histological Classification, Targeted Therapies, and Immunotherapy
    Olga Rodak, Manuel David Peris‐Díaz, Mateusz Olbromski, Marzenna Podhorska‐Okołów, Piotr Dzięgiel · 2021 · Cancers
20. Targeting mutations in cancer
    Michael R. Waarts, Aaron James Stonestrom, Young C. Park, Ross L. Levine · 2022 · Journal of Clinical Investigation
21. Detection of NRG1 Gene Fusions in Solid Tumors
    Sushma Jonna, Rebecca A. Feldman, Jeffrey J. Swensen, Zoran Gatalica, Wolfgang Michael Korn, Hossein Borghaei, Patrick C. Ma, Jorge J. Nieva, Alexander I. Spira, Ari M. Vanderwalde et al. · 2019 · Clinical Cancer Research
22. Novel Third-Generation EGFR Tyrosine Kinase Inhibitors and Strategies to Overcome Therapeutic Resistance in Lung Cancer
    Murtuza, Ayesha, Bulbul, Ajaz, Shen, John Paul, Keshavarzian, Parissa, Woodward, Brian D., Lopez-Diaz, Fernando J., Lippman, Scott M., Husain, Hatim · 2019 · Cancer Research
23. Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review
    Jason D. Merker, Geoffrey R. Oxnard, Carolyn C. Compton, Maximilian Diehn, Patricia A. Hurley, Alexander J. Lazar, Neal Ian Lindeman, Christina M. Lockwood, Alex J. Rai, Richard L. Schilsky et al. · 2018 · Archives of Pathology & Laboratory Medicine
24. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC)
    A. Gelatti, Alexander Edward Dela Cruz Drilon, Fernando Costa Santini · 2019 · Lung Cancer
25. Beyond Osimertinib: The Development of Third-Generation EGFR Tyrosine Kinase Inhibitors For Advanced EGFR+ NSCLC
    Nagasaka, Misako, Zhu, Viola W., Lim, Sun Min, Greco, Michael, Wu, Fengying, Ou, Sai-Hong Ignatius · 2021 · Journal of Thoracic Oncology
26. Exosome-Based Detection of EGFR T790M in Plasma from Non–Small Cell Lung Cancer Patients
    Elena Castellanos-Rizaldos, Dominik G. Grimm, Vasisht R. Tadigotla, James D. Hurley, John Healy, Patricia L. Neal, Mia Sher, Raajdeep Venkatesan, Chris Karlovich, Mitch Raponi et al. · 2018 · Clinical Cancer Research
27. Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial
    Zhijie Wang, Ying Cheng, Tongtong An, Hongjun Gao, Kai Wang, Qing Hua Zhou, Yanping Hu, Yong Song, Cuimin Ding, Feng Peng et al. · 2018 · The Lancet Respiratory Medicine
28. Osimertinib-Induced Cardiotoxicity
    Kartik Anand, Joe Ensor, Barry H. Trachtenberg, Eric Bernicker · 2019 · JACC CardioOncology
29. Recent Advances on the Role of EGFR Tyrosine Kinase Inhibitors in the Management of NSCLC With Uncommon, Non Exon 20 Insertions, EGFR Mutations
    Antonio Passaro, Tony S.K. Mok, Solange Peters, Sanjay Popat, Myung‐Ju Ahn, Filippo de Marinis · 2020 · Journal of Thoracic Oncology
30. Ivonescimab Plus Chemotherapy in Non–Small Cell Lung Cancer With EGFR Variant
    HARMONi-A Study Investigators, Wen‐Feng Fang, Yuanyuan Zhao, Yongzhong Luo, Runxiang Yang, Yan Huang, Zhiyong He, Hui Zhao, Mingjun Li, Kai Li et al. · 2024 · JAMA
31. Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial
    Juliann Chmielecki, Tony S.K. Mok, Yi-Long Lung Cancer Wu, Ji‐Youn Han, Myung‐Ju Ahn, Suresh S. Ramalingam, Thomas John, Isamu Okamoto, James Chih‐Hsin Yang, Frances A. Shepherd et al. · 2023 · Nature Communications
32. Non-Small Cell Lung Cancer Targeted Therapy: Drugs and Mechanisms of Drug Resistance
    Jia‐Jia Wu, Zhenghong Lin · 2022 · International Journal of Molecular Sciences
33. Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M–Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report
    Yang, James Chih-Hsin, Shepherd, Frances A., Kim, Dong-Wan, Lee, Gyeong-Won, Lee, Jong Seok, Chang, Gee-Chen, Lee, Sung Sook, Wei, Yu-Feng, Lee, Yun Gyoo, Laus, Gianluca et al. · 2019 · Journal of Thoracic Oncology
34. Lung cancer in never smokers—the East Asian experience
    Fei Zhou, Caicun Zhou · 2018 · Translational Lung Cancer Research
35. Cancer gene mutation frequencies for the U.S. population
    Gaurav Mendiratta, Eugene Ke, Meraj Aziz, David Liarakos, Melinda M. Tong, Edward C. Stites · 2021 · Nature Communications
36. ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer
    Antonio Passaro, Natasha B. Leighl, Fiona Helen Blackhall, Sanjay Popat, Keith M. Kerr, Myung‐Ju Ahn, Maria E. Arcila, Oscar G. Arrieta, David Planchard, Filippo de Marinis et al. · 2022 · Annals of Oncology
37. Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC)
    Ping‐Chih Hsu, David M. Jablons, Cheng‐Ta Yang, Liang You · 2019 · International Journal of Molecular Sciences
38. Precision Management of Advanced Non–Small Cell Lung Cancer
    Ching‐Yao Yang, James Chih‐Hsin Yang, Pan‐Chyr Yang · 2020 · Annual Review of Medicine
39. Genomic Profiling of Advanced Non–Small Cell Lung Cancer in Community Settings: Gaps and Opportunities
    Martin E Gutierrez, Kelly Choi, Richard Burnham Lanman, Edward J. Licitra, Stan M Skrzypczak, Ruth Pe Benito, Tommy Wu, Srikesh G. Arunajadai, Sukhi Kaur, Harry D. Harper et al. · 2017 · Clinical Lung Cancer
40. EGFR mutation mediates resistance to EGFR tyrosine kinase inhibitors in NSCLC: From molecular mechanisms to clinical research
    Ruifang Dong, Miaolin Zhu, Mingming Liu, Yiting Xu, Liu-Liu Yuan, Jing Bian, Yuan‐Zheng Xia, Lingyi Kong · 2021 · Pharmacological Research
41. Therapeutic potential of pyrrole and pyrrolidine analogs: an update
    N. Jeelan Basha, Suliphuldevara Mathada Basavarajaiah, K. Shyamsunder · 2022 · Molecular Diversity
42. Analytical Validation of a Hybrid Capture–Based Next-Generation Sequencing Clinical Assay for Genomic Profiling of Cell-Free Circulating Tumor DNA
    Clark, Travis A., Chung, Jon H., Kennedy, Mark, Hughes, Jason D., Chennagiri, Niru, Lieber, Daniel S., Fendler, Bernard, Young, Lauren, Zhao, Mandy, Coyne, Michael et al. · 2018 · The Journal of Molecular Diagnostics
43. EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer
    Xueli Nan, Chao Xie, Xueyan Yu, Jie Liu · 2017 · Oncotarget
44. Intrinsic Resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance
    Eric Santoni‐Rugiu, Linea Cecilie Melchior, Edyta Maria Urbanska, Jan Nyrop Jakobsen, Karin de Stricker, Morten Grauslund, Jens Benn Sørensen · 2019 · Cancers
45. Discovery of BLU-945, a Reversible, Potent, and Wild-Type-Sparing Next-Generation EGFR Mutant Inhibitor for Treatment-Resistant Non-Small-Cell Lung Cancer
    Meredith S. Eno, Jason D. Brubaker, John E. Campbell, Chris De Savi, Timothy J. Guzi, Brett D. Williams, Douglas P. Wilson, Kevin J. Wilson, Natasja Brooijmans, Joseph Kim et al. · 2022 · Journal of Medicinal Chemistry
46. Mechanisms of osimertinib resistance and emerging treatment options
    Sabine Schmid, Janice J.N. Li, Natasha B. Leighl · 2020 · Lung Cancer
47. Neoadjuvant Osimertinib With/Without Chemotherapy Versus Chemotherapy Alone for EGFR -Mutated Resectable Non-Small-Cell Lung Cancer: NeoADAURA
    Masahiro Tsuboi, Walter Weder, Carles Escriu, Collin Michael Blakely, Jianxing He, Sanja Đačić, Yasushi Yatabe, Lingmin Zeng, Andrew Walding, Jamie E. Chaft · 2021 · Future Oncology
48. Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With EGFR- or ALK-Rearranged or Translocated Non–Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04)
    Sehhoon Park, Tae Min Kim, Ji‐Youn Han, Gyeong‐Won Lee, Byoung Yong Shim, Yun‐Gyoo Lee, Sang‐We Kim, Il Hwan Kim, Suee Lee, Yu Jung Kim et al. · 2023 · Journal of Clinical Oncology
49. Emerging Treatment Paradigms for EGFR-Mutant Lung Cancers Progressing on Osimertinib: A Review
    Andrew J. Piper‐Vallillo, Lecia Van Dam Sequist, Zofia Piotrowska · 2020 · Journal of Clinical Oncology
50. A New Approach to Predict Progression-free Survival in Stage IV EGFR-mutant NSCLC Patients with EGFR-TKI Therapy
    Jiangdian Song, Jingyun Shi, Di Dong, Mengjie Fang, Wen‐Zhao Zhong, Kun Wang, Ning Wu, Yanqi Huang, Zhenyu Liu, Yue Cheng et al. · 2018 · Clinical Cancer Research
51. Combination Osimertinib and Gefitinib in C797S and T790M EGFR-Mutated Non–Small Cell Lung Cancer
    Surein Arulananda, Hongdo Do, Ashan Musafer, Paul Mitchell, Alexander Dobrovic, Thomas John · 2017 · Journal of Thoracic Oncology
52. Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation
    James Chih‐Hsin Yang, Shirish M. Gadgeel, Lecia Van Dam Sequist, Chien-Liang Wu, Vassiliki A. Papadimitrakopoulou, Wu‐Chou Su, Joseph Fiore, Sanatan Saraf, Harry Raftopoulos, Amita Patnaik · 2018 · Journal of Thoracic Oncology
53. A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy
    Seo‐Young Park, M.-H. Lee, Minjung Seong, S.T. Kim, Jin Hyoung Kang, Byoung Chul Cho, K.H. Lee, E.K. Cho, Jong‐Mu Sun, S.-H. Lee et al. · 2020 · Annals of Oncology
54. Current Landscape of Targeted Therapy in Lung Cancer
    Manasi K. Mayekar, Trever Grant Bivona · 2017 · Clinical Pharmacology & Therapeutics
55. Management of Brain Metastases in Non–Small-Cell Lung Cancer
    Vinicius Ernani, Thomas E. Stinchcombe · 2019 · Journal of Oncology Practice
56. Targeting pan-essential genes in cancer: Challenges and opportunities
    Liang Chang, Paloma A. Ruiz, Takahiro Ito, William R. Sellers · 2021 · Cancer Cell
57. Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC
    Scott N. Gettinger, Matthew David Hellmann, Laura Q.M. Chow, Hossein Borghaei, Scott Joseph Antonia, Julie Renee Brahmer, Jonathan Wade Goldman, David E. Gerber, Rosalyn Anne Juergens, Frances A. Shepherd et al. · 2018 · Journal of Thoracic Oncology
58. Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor–Mutated, MET -Amplified Non–Small Cell Lung Cancer: TATTON
    Ryan James Hartmaier, Aleksandra A. Markovets, Myung‐Ju Ahn, Lecia Van Dam Sequist, Ji‐Youn Han, Byoung Chul Cho, Helena Alexandra Yu, Sang‐We Kim, James Chih‐Hsin Yang, Jong Seok Lee et al. · 2022 · Cancer Discovery
59. Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses
    Tony S.K. Mok, Sang‐We Kim, Yi-Long Lung Cancer Wu, Kazuhiko Nakagawa, Jin‐Ji Yang, Myung‐Ju Ahn, Jie Wang, James Chih‐Hsin Yang, You Lü, Shinji Atagi et al. · 2017 · Journal of Clinical Oncology
60. Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M–Mutated Non–Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor
    Hiroaki Akamatsu, Yukihiro Toi, Hidetoshi Hayashi, Daichi Fujimoto, Motoko Yoshikawa TACHIHARA, Naoki Furuya, Sakiko Otani, Junichi Shimizu, Nobuyuki Katakami, Koichi Azuma et al. · 2021 · JAMA Oncology
61. Tyrosine Kinase Inhibitors for the Treatment of EGFR Mutation-Positive Non–Small-Cell Lung Cancer: A Clash of the Generations
    Riyaz N.H. Shah, Jason Francis Lester · 2019 · Clinical Lung Cancer
62. A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components
    Nilsson, Monique B., Sun, Huiying, Robichaux, Jacqulyne, Pfeifer, Matthias, McDermott, Ultan, Travers, Jon, Diao, Lixia, Xi, Yuanxin, Tong, Pan, Shen, Li et al. · 2020 · Science Translational Medicine
63. Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR-Mutated Advanced NSCLC
    Kim, Youjin, Lee, Boram, Shim, Joon Ho, Lee, Se-Hoon, Park, Woong-Yang, Choi, Yoon-La, Sun, Jong-Mu, Ahn, Jin Seok, Ahn, Myung-Ju, Park, Keunchil · 2019 · Journal of Thoracic Oncology
64. Targeting EGFR L858R/T790M and EGFR L858R/T790M/C797S resistance mutations in NSCLC: Current developments in medicinal chemistry
    Lu, Xiaoyun, Yu, Lei, Zhang, Zhang, Ren, Xiaomei, Smaill, Jeff B., Ding, Ke · 2018 · Medicinal Research Reviews
65. Development of a highly sensitive liquid biopsy platform to detect clinically-relevant cancer mutations at low allele fractions in cell-free DNA
    Davina Gillian Gale, Andrew R. J. Lawson, Karen Howarth, Mikidache Madi, Bradley Durham, Sarah Smalley, John D. Calaway, Shannon Blais, Greg Jones, James Clark et al. · 2018 · PLoS ONE
66. BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
    Yuxiang Ma, Yan Huang, Yuanyuan Zhao, Shen Zhao, Jinhui Xue, Yunpeng Yang, Wen‐Feng Fang, Ye Guo, Yaqian Han, Kunyu Yang et al. · 2024 · The Lancet Oncology
67. SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018)
    Margarita Majem, Óscar Juan, Amelia Insa, Noemí Reguart, José Manuel Trigo, Enric Carcereny, Rosario García‐Campelo, Yolanda García García, María Guirado, Mariano Provencio · 2018 · Clinical & Translational Oncology
68. Analysis of time-to-treatment discontinuation of targeted therapy, immunotherapy, and chemotherapy in clinical trials of patients with non-small-cell lung cancer
    Gideon Michael Blumenthal, Yuexuan Gong, Kenneth L. Kehl, Pallavi Shruti Mishra-Kalyani, Kirsten B. Goldberg, Sean Khozin, Paul Gustav Kluetz, Geoffrey R. Oxnard, Richard Pazdur · 2019 · Annals of Oncology
69. Osimertinib in patients with T790M mutation‐positive, advanced non–small cell lung cancer: Long‐term follow‐up from a pooled analysis of 2 phase 2 studies
    Myung‐Ju Ahn, Chun‐Ming Tsai, Frances A. Shepherd, Lyudmila A. Bazhenova, Lecia Van Dam Sequist, Toyoaki Hida, James Chih‐Hsin Yang, Suresh S. Ramalingam, Tetsuya Mitsudomi, Pasi Antero Janne et al. · 2018 · Cancer
70. An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer
    Ciric To, Tyler S. Beyett, Jaebong Jang, William W. Feng, Magda Bahcall, Heidi M. Haikala, Bo Hee Shin, David E. Heppner, Jaimin K. Rana, Brittaney A. Leeper et al. · 2022 · Nature Cancer
71. RETRACTED: Natural therapeutics and nutraceuticals for lung diseases: Traditional significance, phytochemistry, and pharmacology
    Md. Mominur Rahman, Shabana Bibi, Md. Saidur Rahaman, Firoza Rahman, Fahadul Islam, Muhammad Saad Khan, Mohammad Mehedi Hasan, Anwar Parvez, Md. Abid Hossain, Saila Kabir Maeesa et al. · 2022 · Biomedicine & Pharmacotherapy · Retracted
72. Osimertinib benefit inEGFR-mutant NSCLC patients withT790M-mutation detected by circulating tumour DNA
    Jordi Remón, Caroline Caramella, Cécile Jovelet, Ludovic Lacroix, Andrew R. J. Lawson, Sarah Smalley, Karen Howarth, Davina Gillian Gale, E. Green, Vincent Plagnol et al. · 2017 · Annals of Oncology
73. Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study
    Ying Cheng, Yong He, Wěi Li, Helong Zhang, Qing Hua Zhou, Buhai Wang, Chunling Liu, Andrew Walding, Matilde Saggese, Xiangning Huang et al. · 2021 · Targeted Oncology
74. Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial
    Yang, James Chih-Hsin, Camidge, D. Ross, Yang, Cheng-Ta, Zhou, Jianying, Guo, Renhua, Chiu, Chao-Hua, Chang, Gee-Chen, Shiah, Her-Shyong, Chen, Yuan, Wang, Chin-Chou et al. · 2020 · Journal of Thoracic Oncology
75. Pharmacogenomic Biomarkers for Improved Drug Therapy—Recent Progress and Future Developments
    Volker Martin Lauschke, Lili A. Milani, Magnus Ingelman‐Sundberg · 2017 · The AAPS Journal
76. Start Selective and Rigidify: The Discovery Path toward a Next Generation of EGFR Tyrosine Kinase Inhibitors
    Harald Engelhardt, Dietrich Böse, Mark P. Petronczki, Dirk Scharn, Gerd Bader, Anke Baum, Andreas Bergner, Eugene Chong, Sandra Döbel, Georg Egger et al. · 2019 · Journal of Medicinal Chemistry
77. Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor–Mutated Metastatic Non–Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722
    Tony S.K. Mok, Kazuhiko Nakagawa, Keunchil Park, Yuichiro Ohe, Nicolas Girard, Hye Ryun Kim, Yi-Long Lung Cancer Wu, Justin F. Gainor, Se‐Hoon Lee, Chao‐Hua Chiu et al. · 2024 · Journal of Clinical Oncology
78. Osimertinib for Patients With Leptomeningeal Metastases Associated With EGFR T790M-Positive Advanced NSCLC: The AURA Leptomeningeal Metastases Analysis
    Myung‐Ju Ahn, Chao‐Hua Chiu, Ying Cheng, Ji‐Youn Han, Sarah B. Goldberg, Alastair Greystoke, Jeffrey Crawford, Yanqiu Zhao, Xiangning Huang, Martin G. Johnson et al. · 2019 · Journal of Thoracic Oncology
79. Self-improving generative foundation model for synthetic medical image generation and clinical applications
    Jinzhuo Wang, Kai Wang, Yunfang Yu, Yuxing Lu, Wenchao Xiao, Zhuo Sun, Fei Liu, Zixing Zou, Yuanxu Gao, Lei Yang et al. · 2024 · Nature Medicine
80. Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: Focus on novel therapies
    Melissa Lynne Johnson, Marina Chiara Garassino, Tony S.K. Mok, Tetsuya Mitsudomi · 2022 · Lung Cancer
81. Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer
    Charles Ricordel, Luc Friboulet, Francesco Facchinetti, Jean‐Charles Soria · 2017 · Annals of Oncology
82. Cholesterol promotes EGFR-TKIs resistance in NSCLC by inducing EGFR/Src/Erk/SP1 signaling-mediated ERRα re-expression
    Zhenzhen Pan, Kai Wang, Xiniao Wang, Zhirong Jia, Yuqi Yang, Yalei Duan, Lianzhan Huang, Zhuo‐Xun Wu, Jianye Zhang, Xuansheng Ding · 2022 · Molecular Cancer
83. Recent advances in therapeutic strategies for non-small cell lung cancer
    Po‐Lan Su, Naoki Furuya, Alahmadi Asrar, Christian Diego Rolfo, Zihai Li, David Paul Carbone, Kai He · 2025 · Journal of Hematology & Oncology
84. Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset
    Yuichiro Ohe, Fumio Imamura, Naoyuki Nogami, Isamu Okamoto, Takayasu Kurata, Terufumi Kato, Shunichi Sugawara, Suresh S. Ramalingam, Hirohiko Uchida, Rachel A. Hodge et al. · 2018 · Japanese Journal of Clinical Oncology
85. Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC
    Yi-Long Lung Cancer Wu, Thomas John, Christian Grohé, Margarita Majem, Jonathan Wade Goldman, Sang‐We Kim, Terufumi Kato, Константин Константинович Лактионов, Hữu Vĩnh Vũ, Zhijie Wang et al. · 2021 · Journal of Thoracic Oncology
86. Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/G and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib
    Sai‐Hong Ignatius Ou, Jean Cui, Alexa Betzig Schrock, Michael E. Goldberg, Viola Weijia Zhu, Lee A. Albacker, Philip J. Stephens, Vincent A. Miller, Siraj Mahamed Ali · 2017 · Lung Cancer
87. First- and Second-Generation EGFR-TKIs Are All Replaced to Osimertinib in Chemo-Naive EGFR Mutation-Positive Non-Small Cell Lung Cancer?
    Masayuki Takeda, Kazuhiko Nakagawa · 2019 · International Journal of Molecular Sciences
88. Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial
    Shun Lü, Qiming Wang, Guojun Zhang, Xiaorong Dong, Cheng‐Ta Yang, Yong Song, Gee‐Chen Chang, You Lü, Hongming Pan, Chao‐Hua Chiu et al. · 2021 · Journal of Thoracic Oncology
89. The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV
    Hiroaki Akamatsu, Kiichiro Ninomiya, Hirotsugu Kenmotsu, Masahiro Morise, Haruko Daga, Yasushi Goto, Toshiyuki Kozuki, Satoru Miura, Takaaki Sasaki, Akihiro Tamiya et al. · 2019 · International Journal of Clinical Oncology
90. CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor–Mutated Advanced Non–Small-Cell Lung Cancer
    Pasi Antero Janne, David Planchard, Kunihiko Kobayashi, Ying Cheng, Chee Khoon Lee, Natalia Valdiviezo, Константин Константинович Лактионов, Tsung‐Ying Yang, Yan Yu, Terufumi Kato et al. · 2023 · Journal of Clinical Oncology
91. Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study
    Lin, Chia-Chi, Shih, Jin-Yuan, Yu, Chong-Jen, Ho, Chao-Chi, Liao, Wei-Yu, Lee, Jih-Hsing, Tsai, Tzu-Hsiu, Su, Kang-Yi, Hsieh, Min-Shu, Chang, Yih-Leong et al. · 2018 · The Lancet Respiratory Medicine
92. Complexity of genome sequencing and reporting: Next generation sequencing (NGS) technologies and implementation of precision medicine in real life
    Stefania Morganti, Paolo Tarantino, Emanuela Ferraro, Paolo D’Amico, Giulia Viale, Dario Trapani, Bruno Achutti Duso, Giuseppe Curigliano · 2018 · Critical Reviews in Oncology/Hematology
93. Utility of Genomic Assessment of Blood-Derived Circulating Tumor DNA (ctDNA) in Patients with Advanced Lung Adenocarcinoma
    Maria Clemence Schwaederle, Sandip Pravin Patel, Hatim Husain, Megumi Ikeda, Richard Burnham Lanman, Kimberly C. Banks, AmirAli H. Talasaz, Lyudmila A. Bazhenova, Razelle Kurzrock · 2017 · Clinical Cancer Research
94. Oncogenic alterations in advanced NSCLC: a molecular super-highway
    Alex Friedlaender, Maurice Pérol, Giuseppe Luigi Banna, Kaushal Parikh, Alfredo Addeo · 2024 · Biomarker Research
95. Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma
    Giuseppe Lamberti, Elisa Andrini, Monia Sisi, Alessandro Rizzo, Claudia Parisi, Alessandro Di Federico, Francesco Gelsomino, Andrea Ardizzoni · 2020 · Critical Reviews in Oncology/Hematology
96. Treatments for EGFR-mutant non-small cell lung cancer (NSCLC): The road to a success, paved with failures
    Ki Hyeong Lee · 2017 · Pharmacology & Therapeutics
97. Overcoming EGFRG724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors
    Jana Fassunke, Fabienne Müller, Marina Keul, Sebastian Yves Friedrich Michels, Marcel Andre Dammert, Anna Schmitt, Dennis Plenker, Jonas Lategahn, Carina Heydt, Johannes Brägelmann et al. · 2018 · Nature Communications
98. Detection of Minimal Residual Disease Using ctDNA in Lung Cancer: Current Evidence and Future Directions
    Young Kwang Chae, Michael S. Oh · 2018 · Journal of Thoracic Oncology
99. Targeted Therapy for Cancers: From Ongoing Clinical Trials to FDA-Approved Drugs
    Ha Yeong Choi, Ji‐Eun Chang · 2023 · International Journal of Molecular Sciences
100. Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset
     Byoung Chul Cho, Busayamas Chewaskulyong, Ki Hyeong Lee, Arunee Dechaphunkul, Virote Sriuranpong, Fumio Imamura, Naoyuki Nogami, Takayasu Kurata, Isamu Okamoto, Caicun Zhou et al. · 2018 · Journal of Thoracic Oncology